Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Journal of Immunology Research
Hongshu SuiJiali Yang

Abstract

Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC). However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices. Nowadays, several companion diagnostic assays for PDL1 expression have been introduced for identifying patients who may benefit the immunotherapy. In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments, as compared to the monotherapy of these agents alone. In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for...Continue Reading

References

Apr 12, 2006·The Journal of Experimental Medicine·Mary E KeirArlene H Sharpe
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jul 23, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liza B JohnPhillip K Darcy
Jul 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K AzumaI Okamoto
Oct 29, 2014·British Journal of Cancer·A D'InceccoF Cappuzzo
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Apr 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L ApetohF Ghiringhelli
May 6, 2015·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 15, 2015·BioMed Research International·Fei HanXiaoming Liu
Sep 1, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsXiaoling Zhang
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 22, 2015·Expert Review of Anticancer Therapy·Thu Oanh DangAlexander Drilon
Dec 3, 2015·Translational Lung Cancer Research·Sinead A Noonan, D Ross Camidge
Jan 23, 2016·Expert Opinion on Biological Therapy·Sung Hee LimMyung-Ju Ahn
Feb 11, 2016·Immunotherapy·Bing Xia, Roy S Herbst
Mar 6, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Takehito Shukuya, David P Carbone
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviScott Antonia
Jul 19, 2016·Expert Opinion on Biological Therapy·Jiali YangWilliam C Cho
Aug 25, 2016·The British Journal of Radiology·Richard C WalshawTim M Illidge
Aug 30, 2016·CA: a Cancer Journal for Clinicians·Fernanda G HerreraGeorge Coukos
Oct 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christian ManegoldEverett Vokes
Dec 30, 2016·Cancer Discovery·Valsamo AnagnostouVictor E Velculescu
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Deepa RangachariDaniel B Costa

❮ Previous
Next ❯

Citations

Dec 14, 2018·Bioscience Reports·Chunfeng LiuSongping Wang
Feb 7, 2019·Expert Review of Molecular Diagnostics·Yakup Bozkaya, Ozan Yazıcı
Oct 1, 2019·Current Opinion in Neurology·Nazanin MajdJohn de Groot
May 30, 2020·Cancer Cell International·Zhuo-Zheng LiangTian-Tuo Zhang
Aug 9, 2020·Clinical Epigenetics·Jeong Yeon KimHyunchul Jung
Apr 23, 2020·International Journal of Molecular Sciences·Stephanie Sanders, Waldemar Debinski
Nov 16, 2019·Targeted Oncology·Sohita Dhillon, Yahiya Y Syed
Oct 20, 2020·Frontiers in Oncology·Chaoyue SuJianye Zhang
Sep 18, 2020·Carcinogenesis·Melissa J ConroyJoanne Lysaght
Dec 29, 2020·Frontiers in Cell and Developmental Biology·Yueming ZhangJian Zhang
Jul 17, 2019·Papillomavirus Research·Ian H Frazer, Janin Chandra
Oct 19, 2019·Pharmacology & Therapeutics·Parinaz MehdipourDaniel D De Carvalho
Feb 16, 2021·Neurosurgery·Angus TolandSonika M Dahiya
Nov 13, 2020·Frontiers in Cell and Developmental Biology·Kaijian ZhouGuoxin Liang
Jan 17, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Daniel E HagamanMarites P Melancon
Feb 21, 2021·Archives of Pharmacal Research·Hye-Young Min, Ho-Young Lee
Mar 2, 2021·Therapeutic Advances in Medical Oncology·Jingjing QuJianying Zhou
May 15, 2021·Frontiers in Medicine·Julika Ribbat-IdelSven Perner

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
xenograft

Clinical Trials Mentioned

NCT02453282
NCT02352948
NCT02031458
NCT00730639
NCT00729664
NCT01673867
NCT01642004
NCT01903993
NCT02088112
NCT01633970

Software Mentioned

ALUR

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.